Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700901 | 0.91 | ALOX5 (0.53) | DNM1ALDH1A1TSHREPHX1ALOX5 | |
| SCHEMBL27044028 | 0.89 | DNM1 (0.59) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13474856 | 0.89 | DNM1 (0.59) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL23742227 | 0.89 | DNM1 (0.59) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13474823 | 0.89 | DNM1 (0.59) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL23263732 | 0.85 | ALOX5 (0.55) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL18800947 | 0.83 | DNM1 (0.52) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24294234 | 0.82 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL21984825 | 0.82 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24522348 | 0.82 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | DNM1 745/4885ALDH1A1 1529/4885MEN1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.